[Anti-arrhythmic effectiveness of neogilurhythmal in extrasystolic arrhythmia].
The paper provides the results of differential neogilurythmal therapy in 20 patients with high-grade atrial and ventricular premature contractions in the presence of coronary heart disease. The detection of cardiac arrhythmias and evaluation of the antiarrhythmic efficacy of neogilurythmal were performed by Holter monitoring and transesophageal electrophysiological study. After the baseline studies, the antiarrhythmic efficacy of the drug was evaluated during an acute drug test and then during a 8-day course of the therapy. In the acute drug test, the dose of neogilurythmal was 50% of the daily dosage. The studies indicated that neogilurythmal in a dose of 80 mg/day was beneficial in affecting both the atrial and ventricular extrasystolic arrhythmia. The agent failed to alter heart rate, sinus nodal function and atrioventricular conduction. Thus, neogilurythmal is low toxic and produces no adverse effects when given in the definite dosage range.
Kobuliia
B G
BG
Maĭsuradze
M Z
MZ
Mindadze
K A
KA
Imnadze
G N
GN
Saatashvili
G A
GA
D000328:Adult; D005117:Cardiac Complexes, Premature / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D002648:Child; D003327:Coronary Disease / Q000150:complications; D004562:Electrocardiography; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011219:Prajmaline / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D011219:Prajmaline